MA53981A - Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation - Google Patents
Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisationInfo
- Publication number
- MA53981A MA53981A MA053981A MA53981A MA53981A MA 53981 A MA53981 A MA 53981A MA 053981 A MA053981 A MA 053981A MA 53981 A MA53981 A MA 53981A MA 53981 A MA53981 A MA 53981A
- Authority
- MA
- Morocco
- Prior art keywords
- eso
- methods
- lymphocyte receptors
- lymphocyte
- receptors
- Prior art date
Links
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 title 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749194P | 2018-10-23 | 2018-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53981A true MA53981A (fr) | 2021-09-01 |
Family
ID=68582342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053981A MA53981A (fr) | 2018-10-23 | 2019-10-23 | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210403527A1 (fr) |
| EP (1) | EP3870602A1 (fr) |
| JP (1) | JP2022505679A (fr) |
| KR (1) | KR20210093908A (fr) |
| AU (1) | AU2019364367A1 (fr) |
| CA (1) | CA3117539A1 (fr) |
| EA (1) | EA202191107A1 (fr) |
| MA (1) | MA53981A (fr) |
| WO (1) | WO2020086647A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032544A3 (fr) | 2016-12-08 | 2022-12-21 | Immatics Biotechnologies GmbH | Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant |
| EP3990476A1 (fr) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Protéines de fusion flt3l-fc et procédés d'utilisation |
| PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| EP4171587A2 (fr) * | 2020-06-25 | 2023-05-03 | The Methodist Hospital | Récepteurs de lymphocytes t spécifiques d'antigènes et récepteurs antigéniques chimériques, et méthodes d'utilisation dans la modulation de la signalisation immunitaire pour l'immunothérapie anticancéreuse |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022183076A1 (fr) * | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Thérapie cellulaire immunitaire améliorée ciblant ny-eso-1 |
| WO2022245671A1 (fr) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Méthodes d'utilisation de protéines de fusion flt3l-fc |
| CN118139858A (zh) | 2021-10-28 | 2024-06-04 | 吉利德科学公司 | 吡地嗪-3(2h)-酮衍生物 |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023114433A1 (fr) * | 2021-12-15 | 2023-06-22 | 3T Biosciences, Inc. | Méthodes et systèmes d'évaluation de récepteurs et d'antigènes de cellules immunitaires |
| WO2023122615A1 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023141587A2 (fr) * | 2022-01-20 | 2023-07-27 | 3T Biosciences, Inc. | Compositions de récepteur de lymphocytes t (tcr) et méthodes d'optimisation de lymphocytes t réactifs à l'antigène |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (fr) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Composés cd73 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| JP2703893B2 (ja) | 1985-07-05 | 1998-01-26 | ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ | 外来遺伝子物質を発現する上皮細胞 |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| JP3015383B2 (ja) | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
| DE3851153T2 (de) | 1987-12-11 | 1995-01-05 | Hughes Howard Med Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| JP2002515243A (ja) | 1998-05-19 | 2002-05-28 | アヴィデックス リミテッド | 多価ｔ細胞受容体複合体 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| WO2005113595A2 (fr) * | 2004-05-19 | 2005-12-01 | Avidex Ltd | Recepteurs des lymphocytes t ny-eso a affinite elevee |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| CN107699585A (zh) | 2010-12-09 | 2018-02-16 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
| WO2014160030A2 (fr) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral |
| RU2645256C2 (ru) * | 2013-06-26 | 2018-02-19 | Гуандун Сянсюэ Лайф Сайенсис, Лтд. | Высокостабильный т-клеточный рецептор и способ его получения и применения |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| EP3220926A4 (fr) | 2014-11-17 | 2018-08-08 | Adicet Bio Inc. | Lymphocytes t gamma delta produits par génie génétique |
| HUE064168T2 (hu) | 2015-04-06 | 2024-02-28 | Regeneron Pharma | Humanizált T-sejt által közvetített immunválaszok nem humán állatokban |
| GB201616238D0 (en) * | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
-
2019
- 2019-10-23 EA EA202191107A patent/EA202191107A1/ru unknown
- 2019-10-23 WO PCT/US2019/057543 patent/WO2020086647A1/fr unknown
- 2019-10-23 US US17/287,643 patent/US20210403527A1/en active Pending
- 2019-10-23 AU AU2019364367A patent/AU2019364367A1/en active Pending
- 2019-10-23 KR KR1020217015373A patent/KR20210093908A/ko active Search and Examination
- 2019-10-23 MA MA053981A patent/MA53981A/fr unknown
- 2019-10-23 EP EP19804919.9A patent/EP3870602A1/fr active Pending
- 2019-10-23 JP JP2021522096A patent/JP2022505679A/ja active Pending
- 2019-10-23 CA CA3117539A patent/CA3117539A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020086647A8 (fr) | 2020-05-28 |
| WO2020086647A1 (fr) | 2020-04-30 |
| EA202191107A1 (ru) | 2021-09-17 |
| CA3117539A1 (fr) | 2020-04-30 |
| AU2019364367A1 (en) | 2021-05-27 |
| KR20210093908A (ko) | 2021-07-28 |
| JP2022505679A (ja) | 2022-01-14 |
| EP3870602A1 (fr) | 2021-09-01 |
| US20210403527A1 (en) | 2021-12-30 |
| CN113454110A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53981A (fr) | Récepteurs de lymphocytes t de ny-eso-1 et leurs procédés d'utilisation | |
| MA55136A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA51848A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52501A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52765A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52496A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA47265A (fr) | Récepteurs de lymphocytes t qui se lient à ny-eso-1 et méthodes d'utilisation de ces derniers | |
| MA56548A (fr) | Récepteurs de lymphocytes t mage-a4 et leurs procédés d'utilisation | |
| MA50077A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA48772A (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
| MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA55890A (fr) | Modulateurs de thr-beta et leurs procédés d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA53235A (fr) | Indoles substitués et procédés d'utilisation associés | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA40721A (fr) | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |